Christian Marth, MD, PhD, discusses implications of the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.
EP. 1: Prognosis and Survival Outcomes for Advanced/Recurrent Endometrial Cancer
Christian Marth, MD, PhD, highlights the prognosis and survival outcomes for patients who are diagnosed with advanced or recurrent endometrial cancer.
EP. 2: Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer
Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.
EP. 3: Exploring Unmet Needs for the LEAP-001 Trial in Advanced Endometrial Cancer
Christian Marth, MD, PhD, discusses the unmet needs that led to the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.
EP. 4: Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer
Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.
EP. 5: Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer
Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer